GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6535 RS 56812 hydrochlorideSummary: 5-HT3 partial agonist -
B6536 RS 67506 hydrochlorideSummary: potent and selective 5-HT4 partial agonist -
B6541 AH 11110 hydrochlorideSummary: α1B-AR ligand,subtype-selective -
B6545 N-DesmethylclozapineSummary: 5-HT2C serotonin receptor antagonist -
B6548 RS 16566 dihydrochlorideSummary: ligand for the (R)-zacopride binding site -
B6550 LY 225910Summary: CCK2 receptor antagonist -
B6552 CGP 20712 dihydrochlorideTarget: adrenoceptorSummary: β1 antagonist,highly potent and selective -
B6553 Nisoxetine hydrochlorideSummary: noradrenalin uptake inhibitor -
B6558 CP 93129 dihydrochlorideSummary: 5-HT1B agonist, potent and highly selective -
B6559 4-P-PDOTSummary: Melatonin receptor antagonist

